UPDATE: Appeals Court Decides Isolated DNA Patentable, Myriad's Analytical Method Claims Not | GenomeWeb

This article was updated July 31 from an earlier version posted July 29. The updated version includes additional analysis on the lawsuit and comments from Duke University's Robert Cook-Deegan.

By Turna Ray

While ruling that isolated gene sequences are not products of nature and are therefore patentable, the Court of Appeals for the Federal Circuit last week deemed several of Myriad Genetics' method claims that describe "comparing" and "analyzing" gene sequences invalid.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.